St. Jude to begin Angstrom ICD implants in Europe this fall, firm says at Piper Jaffray conference.
This article was originally published in The Gray Sheet
Executive Summary
ST. JUDE TO BEGIN IMPLANTING ANGSTROM SERIES OF ICDs IN EUROPE by the end of September, Terry Shepherd, acting chief financial officer, said June 18 at the Piper Jaffray investment conference in Minneapolis. The new line of 44 cc single-chamber implantable cardioverter defibrillators, which were developed by the firm's Ventritex unit, includes the Angstrom II, as well as a more advanced version called the Angstrom MD, Shepherd said. St. Jude plans simultaneous premarket approval application supplement submissions to FDA, the company says.